Generation of optimized and urokinase-targeted oncolytic Sendai virus vectors applicable for various human malignancies

Gene Therapy

Volumn 16, Issue 3, 2009, Pages 392-403

  Kinoh, H ^a   Inoue, M ^b   Komaru, A ^a   Ueda, Y ^a   Hasegawa, M ^b   Yonemitsu, Y ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b DNAVEC Corporation   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE; ONCOLYTIC VIRUS; TRYPSIN; UROKINASE; VIRUS VECTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL KILLING; CELL SPREADING; CONTROLLED STUDY; CYTOPLASM; DNA MODIFICATION; DRUG TARGETING; HUMAN; HUMAN CELL; KIDNEY CANCER; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; ONCOLYTIC VIROTHERAPY; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; SENDAI VIRUS; SYNCYTIUM; TUMOR CELL;

ANIMALS; FEMALE; GENETIC VECTORS; GIANT CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MUTAGENESIS, SITE-DIRECTED; NEOPLASM TRANSPLANTATION; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PEPTIDE FRAGMENTS; SENDAI VIRUS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

SENDAI VIRUS;

EID: 62549133989     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.167     Document Type: Article

References (27)

1. Aghi M, Martuza RL. Oncolytic viral therapies - the clinical experience. Oncogene 2005; 24: 7802-7816.
2. Bell J. Replicating oncolytic virus therapeutics - Third International Meeting. IDrugs 2005; 8: 360-363.
3. Tashiro M, McQueen NL, Seto JT. Determinants of organ tropism of sendai virus. Front Biosci 1999; 4: D642-D645.
4. Li HO, Zhu YF, Asakawa M, Kuma H, Hirata T, Ueda Y et al. A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J Virol 2000; 74: 6564-6569.
5. Inoue M, Tokusumi Y, Ban H, Kanaya T, Shirakura M, Tokusumi T et al A new Sendai virus vector deficient in the matrix gene does not form virus particles and shows extensive cell-to-cell spreading. J Virol 2003; 77: 6419-6429.
6. Inoue M, Tokusumi Y, Ban H, Shirakura M, Kanaya T, Yoshizaki M et al Recombinant Sendai virus vectors deleted in both the matrix and the fusion genes: Efficient gene transfer with preferable properties. J Gene Med 2004; 6: 1069-1081.
7. Yoshizaki M, Hironaka T, Iwasaki H, Ban H, Tokusumi Y, Iida A et al Naked Sendai virus vector lacking all of the envelope-related genes: reduced cytopathogenicity and immunogenicity. J Gene Med 2006; 8: 1151-1159.
8. Kinoh H, Inoue M, Washizawa K, Yamamoto T, Fujikawa S, Tokusumi Y et al. Generation of a recombinant Sendai virus that is selectively activated and lyses human tumor cells expressing matrix metalloproteinases. Gene Therapy 2004; 11: 1137-1145.
9. Rein A, Mirro J, Haynes JG, Ernst SM, Nagashima K. Function of the cytoplasmic domain of a retroviral transmembrane protein: P15E-p2E cleavage activates the membrane fusion capability of the murine leukemia virus Env protein. J Virol 1994; 68: 1773-1781.
10. Cathomen T, Naim HY, Cattaneo R. Measles viruses with altered envelope protein cytoplasmic tails gain cell fusion competence. J Virol 1998; 72: 1224-1234.
11. Ke SH, Coombs GS, Tachias K, Corey DR, Madison EL. Optimal subsite occupancy and design of a selective inhibitor of urokinase. J Biol Chem 1997; 272: 20456-20462.
12. Springfeld C, von Messling V, Frenzke M, Ungerechts G, Buchholz CJ, Cattaneo R. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res 2006; 66: 7694-7700.
13. Ke SH, Coombs GS, Tachias K, Corey DR, Madison EL. Optimal subsite occupancy and design of a selective inhibitor of urokinase. J Biol Chem 1997; 272: 20456-20462.
14. Ding L, Coombs GS, Strandberg L, Navre M, Corey DR, Madison EL. Origins of the specificity of tissue-type plasminogen activator. Proc Natl Acad Sci USA 1995; 92: 7627-7631.
15. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-174.
16. Dano K, Behrendt N, Hoyer-Hansen G, Johnsen M, Lund LR, Ploug M et al Plasminogen activation and cancer. Thromb Haemost 2005; 93 676-681.
17. Gage PJ, Levine M, Glorioso JC. Syncytium-inducing mutations localize to two discrete regions within the cytoplasmic domain of herpes simplex virus type 1 glycoprotein B. J Virol 1993; 67: 2191-2201.
18. Tahara M, Takeda M, Yanagi Y. Altered interaction of the matrix protein with the cytoplasmic tail of hemagglutinin modulates measles virus growth by affecting virus assembly and cell-cell fusion. J Virol 2007; 81: 6827-6836.
19. Johnson KJ, Peng KW, Allen C, Russell SJ, Galanis E. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction. Gene Therapy 2003; 10: 725-732.
20. Allen C, McDonald C, Giannini C, Peng KW, Rosales G, Russell SJ et al Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas. J Gene Med 2004; 6: 1216-1227.
21. Harris JL, Backes BJ, Leonetti F, Mahrus S, Ellman JA, Craik CS. Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. Proc Natl Acad Sci USA 2000; 97: 7754-7759.
22. Bateman AR, Harrington KJ, Kottke T, Ahmed A, Melcher AA, Gough MJ et al. Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Res 2002; 62: 6566-6578.
23. Diaz RM, Bateman A, Emiliusen L, Fielding A, Trono D, Russell SJ et al. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. Gene Therapy 2000; 7: 1656-1663.
24. Linardakis E, Bateman A, Phan V, Ahmed A, Gough M, Olivier K et al Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res 2002; 62: 5495-5504.
25. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991; 108 193-199.
26. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980; 102: 196-202.
27. Togawa D, Koshino T, Saito T, Takagi T, Machida J. Highly activated matrix metalloproteinase-2 secreted from clones of metastatic lung nodules of nude mice injected with human fibrosarcoma HT1080. Cancer Lett 1999; 146: 25-33.